Amyloid-Like Fibril Formation by Tachykinin Neuropeptides and Its Relevance to Amyloid β-Protein Aggregation and Toxicity

Cell Biochemistry and Biophysics

Volumn 64, Issue 1, 2012, Pages 29-44

  Singh, Pradeep K ^a   Maji, Samir K ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Amyloids; Fibrils; Functions; Neuropeptides; Peptide

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (25 35); AMYLOID BETA-PROTEIN (25-35); CONGO RED; HEPARIN; KASSININ; PEPTIDE FRAGMENT; PHYSALAEMIN; SUBSTANCE P; THIAZOLE DERIVATIVE; THIOFLAVINE;

ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; CHEMISTRY; CIRCULAR DICHROISM; DRUG EFFECT; ELECTRON MICROSCOPY; HUMAN; METHODOLOGY; NERVE CELL; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; TOXICITY TESTING; TUMOR CELL LINE; ULTRASTRUCTURE;

ALGORITHMS; AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PEPTIDES; CELL LINE, TUMOR; CIRCULAR DICHROISM; CONGO RED; HEPARIN; HUMANS; KASSININ; MICROSCOPY, ELECTRON; NEURONS; PEPTIDE FRAGMENTS; PHYSALAEMIN; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SUBSTANCE P; THIAZOLES; TOXICITY TESTS;

MAMMALIA;

EID: 84865560144     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-012-9364-z     Document Type: Article

References (65)

1. Chiti, F., & Dobson, C. M. (2006). Protein misfolding, functional amyloid, and human disease. Annual Review of Biochemistry, 75, 333-366.
2. Maji, S. K., Wang, L., Greenwald, J., & Riek, R. (2009). Structure-activity relationship of amyloid fibrils. FEBS Letters, 583, 2610-2617.
3. Tycko, R. (2006). Molecular structure of amyloid fibrils: Insights from solid-state NMR. Quarterly Reviews of Biophysics, 39, 1-55.
4. Klunk, W. E., Jacob, R. F., & Mason, R. P. (1999). Quantifying amyloid by Congo red spectral shift assay. Methods in Enzymology, 309, 285-305.
5. LeVine, H. (1999). Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods in Enzymology, 309, 274-284.
6. Sunde, M., & Blake, C. (1997). The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Advances in Protein Chemistry, 50, 123-159.
7. Sunde, M., Serpell, L. C., Bartlam, M., Fraser, P. E., Pepys, M. B., & Blake, C. C. (1997). Common core structure of amyloid fibrils by synchrotron X-ray diffraction. Journal of Molecular Biology, 273, 729-739.
8. Dobson, C. M. (1999). Protein misfolding, evolution and disease. Trends in Biochemical Sciences, 24, 329-332.
9. Huff, M. E., Balch, W. E., & Kelly, J. W. (2003). Pathological and functional amyloid formation orchestrated by the secretory pathway. Current Opinion in Structural Biology, 13, 674-682.
10. Fowler, D. M., Koulov, A. V., Alory-Jost, C., Marks, M. S., Balch, W. E., & Kelly, J. W. (2006). Functional amyloid formation within mammalian tissue. PLoS Biology, 4, e6.
11. Fowler, D. M., Koulov, A. V., Balch, W. E., & Kelly, J. W. (2007). Functional amyloid-from bacteria to humans. Trends in Biochemical Sciences, 32, 217-224.
12. Jacob, R., Anoop, A., Singh, P., & Maji, S. (2010). Native Functions of Amyloid. In D. A. Stein (Ed.), Protein aggregation (pp. 79-109). New York: Nova Science Publishers, Inc.
13. Maji, S. K., Perrin, M. H., Sawaya, M. R., Jessberger, S., Vadodaria, K., Rissman, R. A., et al. (2009). Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science, 325, 328-332.
14. Mankar, S., Anoop, A., Sen, S., & Maji, S. K. (2011). Nanomaterials: Amyloids reflect their brighter side. Nano Reviews, 2, 6032. doi: 10. 3402/nano. v2i0. 6032.
15. Gras, S. L. (2009). Surface- and solution-based assembly of amyloid fibrils for biomedical and nanotechnology applications. Advances in Chemical Engineering, 35, 161-209.
16. Gras, S. L., Tickler, A. K., Squires, A. M., Devlin, G. L., Horton, M. A., Dobson, C. M., et al. (2008). Functionalised amyloid fibrils for roles in cell adhesion. Biomaterials, 29, 1553-1562.
17. Gazit, E. (2007). Self-assembled peptide nanostructures: The design of molecular building blocks and their technological utilization. Chemical Society Reviews, 36, 1263-1269.
18. Zhang, S., Marini, D. M., Hwang, W., & Santoso, S. (2002). Design of nanostructured biological materials through self-assembly of peptides and proteins. Current Opinion in Chemical Biology, 6, 865-871.
19. Pernow, B. (1983). Substance P. Pharmacological Reviews, 35, 85-141.
20. Severini, C., Improta, G., Falconieri-Erspamer, G., Salvadori, S., & Erspamer, V. (2002). The tachykinin peptide family. Pharmacological Reviews, 54, 285-322.
21. Schwyzer, R. (1987). Membrane-assisted molecular mechanism of neurokinin receptor subtype selection. EMBO Journal, 6, 2255-2259.
22. Grace, C. R., & Cowsik, S. M. (2011). Solution conformation of non-mammalian tachykinin physalaemin in lipid micelles by NMR. Biopolymers, 96, 252-259.
23. Maggio, J. E. (1988). Tachykinins. Annual Review of Neuroscience, 11, 13-28.
24. Helke, C. J., Krause, J. E., Mantyh, P. W., Couture, R., & Bannon, M. J. (1990). Diversity in mammalian tachykinin peptidergic neurons: Multiple peptides, receptors, and regulatory mechanisms. FASEB Journal, 4, 1606-1615.
25. Merighi, A., Polak, J. M., Gibson, S. J., Gulbenkian, S., Valentino, K. L., & Peirone, S. M. (1988). Ultrastructural studies on calcitonin gene-related peptide-, tachykinins- and somatostatin-immunoreactive neurones in rat dorsal root ganglia: Evidence for the colocalization of different peptides in single secretory granules. Cell and Tissue Research, 254, 101-109.
26. Ma, G. Q., Wang, B., Wang, H. B., Wang, Q., & Bao, L. (2008). Short elements with charged amino acids form clusters to sort protachykinin into large dense-core vesicles. Traffic, 9, 2165-2179.
27. Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990). Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides. Science, 250, 279-282.
28. El-Agnaf, O. M., Irvine, G. B., Fitzpatrick, G., Glass, W. K., & Guthrie, D. J. (1998). Comparative studies on peptides representing the so-called tachykinin-like region of the Alzheimer Aβ peptide [Aβ(25-35)]. Biochemical Journal, 336(Pt 2), 419-427.
29. Kowall, N. W., Beal, M. F., Busciglio, J., Duffy, L. K., & Yankner, B. A. (1991). An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P. Proceedings of the National Academy of Science of the United States of America, 88, 7247-7251.
30. Fernandez-Escamilla, A. M., Rousseau, F., Schymkowitz, J., & Serrano, L. (2004). Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nature Biotechnology, 22, 1302-1306.
31. Maurer-Stroh, S., Debulpaep, M., Kuemmerer, N., de la Paz, M. L., Martins, I. C., Reumers, J., et al. (2010). Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nature Methods, 7, 237-242.
32. Suk, J. Y., Zhang, F., Balch, W. E., Linhardt, R. J., & Kelly, J. W. (2006). Heparin accelerates gelsolin amyloidogenesis. Biochemistry, 45, 2234-2242.
33. Kisilevsky, R. (2000). Review: Amyloidogenesis-Unquestioned answers and unanswered questions. Journal of Structural Biology, 130, 99-108.
34. Yamamoto, S., Yamaguchi, I., Hasegawa, K., Tsutsumi, S., Goto, Y., Gejyo, F., et al. (2004). Glycosaminoglycans enhance the trifluoroethanol-induced extension of β2-microglobulin-related amyloid fibrils at a neutral pH. Journal of the American Society of Nephrology, 15, 126-133.
35. Cohlberg, J. A., Li, J., Uversky, V. N., & Fink, A. L. (2002). Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry, 41, 1502-1511.
36. Supattapone, S. (2004). Prion protein conversion in vitro. Journal of Molecular Medicine, 82, 348-356.
37. Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., & Crowther, R. A. (1996). Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature, 383, 550-553.
38. Maji, S. K., Schubert, D., Rivier, C., Lee, S., Rivier, J. E., & Riek, R. (2008). Amyloid as a depot for the formulation of long-acting drugs. PLoS Biology, 6, e17.
39. Kolset, S. O., Prydz, K., & Pejler, G. (2004). Intracellular proteoglycans. Biochem Journal, 379, 217-227.
40. Zanini, A., Giannattasio, G., Nussdorfer, G., Margolis, R. K., Margolis, R. U., & Meldolesi, J. (1980). Molecular organization of prolactin granules. II. Characterization of glycosaminoglycans and glycoproteins of the bovine prolactin matrix. Journal of Cell Biology, 86, 260-272.
41. Maji, S. K., Amsden, J. J., Rothschild, K. J., Condron, M. M., & Teplow, D. B. (2005). Conformational dynamics of amyloid β-protein assembly probed using intrinsic fluorescence. Biochemistry, 44, 13365-13376.
42. Lakowicz, J. R. (1999). Principles of fluorescence spectroscopy (2nd ed.). New York: Kluwer/Plenum.
43. Buck, M. (1998). Trifluoroethanol and colleagues: Cosolvents come of age. Recent studies with peptides and proteins. Quarterly Reviews of Biophysics, 31, 297-355.
44. Fezoui, Y., & Teplow, D. B. (2002). Kinetic studies of amyloid β-protein fibril assembly-Differential effects of α-helix stabilization. Journal of Biological Chemistry, 277, 36948-36954.
45. Anderson, V. L., Ramlall, T. F., Rospigliosi, C. C., Webb, W. W., & Eliezer, D. (2010). Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation. Proceedings of the National Academy of Sciences of the United States of America, 107, 18850-18855.
46. Munishkina, L. A., Phelan, C., Uversky, V. N., & Fink, A. L. (2003). Conformational behavior and aggregation of α-synuclein in organic solvents: Modeling the effects of membranes. Biochemistry, 42, 2720-2730.
47. Hardy, J., & Selkoe, D. J. (2002). Medicine-The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297, 353-356.
48. Klein, W. L., Stine, W. B., Jr, & Teplow, D. B. (2004). Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiology of Aging, 25, 569-580.
49. Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., et al. (2011). In vivo demonstration that α-synuclein oligomers are toxic. Proceedings of the National Academy of Sciences of the United Sciences of America, 108, 4194-4199.
50. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., et al. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486-489.
51. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63.
52. Harper, J. D., & Lansbury, P. T., Jr. (1997). Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annual Review of Biochemistry, 66, 385-407.
53. Wright, C. F., Teichmann, S. A., Clarke, J., & Dobson, C. M. (2005). The importance of sequence diversity in the aggregation and evolution of proteins. Nature, 438, 878-881.
54. Han, H. Y., Weinreb, P. H., & Lansbury, P. T. (1995). The core Alzheimer's peptide Nac forms amyloid fibrils which seed and are seeded by β-Amyloid-Is NAC a common trigger or target in neurodegenerative disease? Chemistry & Biology, 2, 163-169.
55. Cherny, I., & Gazit, E. (2008). Amyloids: Not only pathological agents but also ordered nanomaterials. Angewandte Chemie (International ed. in English), 47, 4062-4069.
56. Hamodrakas, S. J. (2011). Protein aggregation and amyloid fibril formation prediction software from primary sequence: Towards controlling the formation of bacterial inclusion bodies. FEBS Journal, 278, 2428-2435.
57. Kyte, J., & Doolittle, R. F. (1982). A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology, 157, 105-132.
58. Chou, P. Y., & Fasman, G. D. (1978). Prediction of the secondary structure of proteins from their amino acid sequence. Advances in Enzymology and Related Areas of Molecular Biology, 47, 45-148.
59. Monsellier, E., Ramazzotti, M., Taddei, N., & Chiti, F. (2010). A computational approach for identifying the chemical factors involved in the glycosaminoglycans-mediated acceleration of amyloid fibril formation. PLoS One, 5, e11363.
60. Valle-Delgado, J. J., Alfonso-Prieto, M., de Groot, N. S., Ventura, S., Samitier, J., Rovira, C., et al. (2010). Modulation of Aβ42 fibrillogenesis by glycosaminoglycan structure. FASEB Journal, 24, 4250-4261.
61. Bourgault, S., Solomon, J. P., Reixach, N., & Kelly, J. W. (2011). Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry, 50, 1001-1015.
62. Meng, F., Abedini, A., Song, B., & Raleigh, D. P. (2007). Amyloid formation by pro-islet amyloid polypeptide processing intermediates: Examination of the role of protein heparan sulfate interactions and implications for islet amyloid formation in type 2 diabetes. Biochemistry, 46, 12091-12099.
63. Sadqi, M., Hernandez, F., Pan, U. M., Perez, M., Schaeberle, M. D., Avila, J., et al. (2002). α-helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry, 41, 7150-7155.
64. Paci, E., Gsponer, J., Salvatella, X., & Vendruscolo, M. (2004). Molecular dynamics studies of the process of amyloid aggregation of peptide fragments of transthyretin. Journal of Molecular Biology, 340, 555-569.
65. Abedini, A., & Raleigh, D. P. (2009). A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. Protein Engineering, Design and Selection, 22, 453-459.